Literature DB >> 17032404

Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States.

Luciana McLean1, Tushar Patel.   

Abstract

BACKGROUND/AIMS: Despite the global increase in the incidence of intrahepatic cholangiocarcinoma, regional variations occur. To assess the potential contribution of racial/ethnic factors, we assessed the epidemiology of these cancers in different racial and ethnic groups in the United States.
METHODS: Disease prevalence, mortality and survival rates for different racial and ethnic groups were obtained from the surveillance, epidemiology and end results survey database.
RESULTS: The age-adjusted prevalence was highest for Hispanics (1.22 per 100 000) and lowest for Blacks (0.3 per 100 000). Age-adjusted mortality rates were higher for American Indian/Alaska Natives and Asian/Pacific Islanders compared with other groups. However, mortality rates increased by greater than 3.5% annual for all racial or ethnic groups except for American Indian/Pacific Islanders in whom mortality rates decreased by 0.2% annually. The increase in mortality rates was greatest for Hispanic women aged between 40 and 49 years. Prevalence and survival were significantly higher in Hispanic women in contrast to gender differences observed in other groups.
CONCLUSIONS: Significant racial and ethnic variations occur in the epidemiology of intrahepatic cholangiocarcinoma within geographically defined regions in the United States These may reflect genetic, socioeconomic or cultural predispositions to cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17032404     DOI: 10.1111/j.1478-3231.2006.01350.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  45 in total

1.  Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases.

Authors:  N Namwat; J Puetkasichonpasutha; W Loilome; P Yongvanit; A Techasen; A Puapairoj; B Sripa; W Tassaneeyakul; N Khuntikeo; S Wongkham
Journal:  J Gastroenterol       Date:  2010-11-13       Impact factor: 7.527

Review 2.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 3.  Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.

Authors:  Halim Charbel; Firas H Al-Kawas
Journal:  Curr Gastroenterol Rep       Date:  2011-04

Review 4.  Epidemiology and risk factors: intrahepatic cholangiocarcinoma.

Authors:  Amar Gupta; Elijah Dixon
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 5.  Current status of peroral cholangioscopy in biliary tract diseases.

Authors:  Stefania Ghersi; Lorenzo Fuccio; Marco Bassi; Carlo Fabbri; Vincenzo Cennamo
Journal:  World J Gastrointest Endosc       Date:  2015-05-16

Review 6.  [Diagnostics and treatment of cholangiocellular carcinoma].

Authors:  L Zender; N P Malek
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

7.  Peroral Cholangiopancreatoscopy: New Advances Bring New Concerns.

Authors:  Marta Gravito-Soares; Nuno Almeida
Journal:  GE Port J Gastroenterol       Date:  2018-01-15

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

9.  Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma.

Authors:  Anchalee Techasen; Nisana Namwat; Watcharin Loilome; Pornpan Bungkanjana; Narong Khuntikeo; Anucha Puapairoj; Patcharee Jearanaikoon; Hideyuki Saya; Puangrat Yongvanit
Journal:  Med Oncol       Date:  2012-08-19       Impact factor: 3.064

Review 10.  Genetic and epigenetic changes associated with cholangiocarcinoma: from DNA methylation to microRNAs.

Authors:  Monique Stutes; Steven Tran; Sharon DeMorrow
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.